Feasibility of α-fetoprotein as a diagnostic tool for hepatocellular carcinoma in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The aim of this study was to evaluate the feasibility of α-fetoprotein (AFP) as a diagnostic tool for hepatocellular carcinoma (HCC) in Korean patients. Methods: We retrospectively reviewed the medical records of HCC and cirrhosis patients at three hospitals. For each HCC patient, a cirrhosis patient matched for age, sex, etiology, and Child-Pugh classification was selected by simple random sampling. The performance of AFP in the diagnosis of HCC was determined using receiver operating characteristic curve analysis. Results: A total of 732 patients with HCC or cirrhosis were selected for each case and the control groups. The mean age was 54 years, and 72.4% of patients were male. The mean serum AFP levels in the HCC group and cirrhosis group were 3,315.6 and 117.2 ng/mL, respectively (p < 0.001). The area under the receiver operating characteristic curve for all HCC patients was 0.757. The sensitivity, specificity, and positive predictive value of AFP was 50.55%, 87.70%, and 80.43%, respectively, at a cut-off of 20 ng/mL; 37.70%, 95.90%, and 90.20%, respectively, at a cutoff of 100 ng/mL, and 30.05%, 97.27%, and 91.67%, respectively, at a cut-off of 200 ng/mL. A cut-off of 100 ng/mL was more sensitive than one of 200 ng/mL with equivalent specificity and positive predictive value. Conclusions: The cut-off AFP value for early-stage HCC was 17.4 ng/mL. Our study cautiously suggests that AFP has a role in the diagnosis of HCC, and that the appropriate value of AFP for the diagnosis of HCC may be 100 ng/mL rather than 200 ng/mL.
Abstract
Background/Aims: The aim of this study was to evaluate the feasibility of α-fetoprotein (AFP) as a diagnostic tool for hepatocellular carcinoma (HCC) in Korean patients. Methods: We retrospectively reviewed the medical records of HCC and cirrhosis patients at three hospitals. For each HCC patient, a cirrhosis patient matched for age, sex, etiology, and Child-Pugh classification was selected by simple random sampling. The performance of AFP in the diagnosis of HCC was determined using receiver operating characteristic curve analysis. Results: A total of 732 patients with HCC or cirrhosis were selected for each case and the control groups. The mean age was 54 years, and 72.4% of patients were male. The mean serum AFP levels in the HCC group and cirrhosis group were 3,315.6 and 117.2 ng/mL, respectively (p < 0.001). The area under the receiver operating characteristic curve for all HCC patients was 0.757. The sensitivity, specificity, and positive predictive value of AFP was 50.55%, 87.70%, and 80.43%, respectively, at a cut-off of 20 ng/mL; 37.70%, 95.90%, and 90.20%, respectively, at a cutoff of 100 ng/mL, and 30.05%, 97.27%, and 91.67%, respectively, at a cut-off of 200 ng/mL. A cut-off of 100 ng/mL was more sensitive than one of 200 ng/mL with equivalent specificity and positive predictive value. Conclusions: The cut-off AFP value for early-stage HCC was 17.4 ng/mL. Our study cautiously suggests that AFP has a role in the diagnosis of HCC, and that the appropriate value of AFP for the diagnosis of HCC may be 100 ng/mL rather than 200 ng/mL.
참고문헌 (22)
- Velazquez RF, "Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis", Hepatology, 37, pp.520~527 (2003)
- Bruix J, "Treatment of hepatocellular carcinoma", Hepatology, 25, pp.259~262 (1997)
- Collier J, "Screening for hepatocellular carcinoma", Hepatology, 27, pp.273~278 (1998)
- Terentiev AA, "Alpha-fetoprotein: a renaissance", Tumour Biol, 34, pp.2075~2091 (2013)
- Bruix J, "Management of hepatocellular carcinoma", Hepatology, 42, pp.1208~1236 (2005)
- Park JW, "Practice guideline for diagnosis and treatment of hepatocellular carcinoma", Korean J Hepatol, 10, pp.88~98 (2004)
- Soresi M, "Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma", Anticancer Res, 23, pp.1747~1753 (2003)
- Bruix J, "Management of hepatocellular carcinoma:an update", Hepatology, 53, pp.1020~1022 (2011)
- Cedrone A, "Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350Western patients", Hepatogastroenterology, 47, pp.1654~1658 (2000)
- Gambarin-Gelwan M, "Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation", Am J Gastroenterol, 95, pp.1535~1538 (2000)
- Gupta S, "Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C: a systematic review and critical analysis", Ann Intern Med, 139, pp.46~50 (2003)
- European Association for Study of Liver, "EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma", Eur J Cancer, 48, pp.599~641 (2012)
- Chan SL, "Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass", HPB, 16, pp.366~372 (2014)
- Sanai FM, "Assessment of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma in Middle Eastern patients", Dig Dis Sci, 55, pp.3568~3575 (2010)
- Nguyen MH, "Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepati-tis C virus cirrhosis", Hepatology, 36, pp.410~417 (2002)
- Liu C, "Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma", World J Gastroenterol, 19, pp.1811~1819 (2013)
- Matsushita N, "Investigation of ornithine carbamoyltransferase as a biomarker of liver cirrhosis", Intern Med, 53, pp.1249~1257 (2014)
- McGlynn KA, "The global epidemiology of hepatocellular carcinoma: present and future", Clin Liver Dis, 15, pp.223~243 (2011)
- Te HS, "Epidemiology of hepatitis B and C viruses: a global overview", Clin Liver Dis, 14, pp.1~21 (2010)
- Trevisani F, "Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status", J Hepatol, 34, pp.570~575 (2001)
- Marrero JA, "Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma", Gastroenterology, 137, pp.110~118 (2009)
- Xu JB, "Value of alpha-fetoprotein and clinical characteristics in patients with liver neoplasm", Neoplasma, 61, pp.218~224 (2014)